Todd V. Brennan, MD, MS, FACS
- The doctor practices in an office or specialty that we currently do not survey.
- The doctor has not yet received the minimum number of patient satisfaction surveys (30) to be eligible for display.
310-423-7408
Fax: 310-423-0234
- The doctor practices in an office or specialty that we currently do not survey.
- The doctor has not yet received the minimum number of patient satisfaction surveys (30) to be eligible for display.
Todd V. Brennan, MD, MS, FACS
Scheduling
In person visits
Fax: 310-423-0234
Comprehensive Transplant Center
8900 Beverly Blvd - 3rd Floor
Los Angeles, CA
34.076892 -118.386309From You
- The doctor practices in an office or specialty that we currently do not survey.
- The doctor has not yet received the minimum number of patient satisfaction surveys (30) to be eligible for display.
Todd V. Brennan, MD, MS, FACS
Languages
- English,
Gender
Male
Experience
23 Years
Locations
Experience
Specialties
Area in which a healthcare provider is highly trained and often board certified.
2
- Surgery Transplant Surgery
- Surgery-General Surgery
Sub Specialties
A focused area of clinical knowledge and skills within a specialty. Example: a neurology specialist focused on stroke treatment.
2
- Liver Transplant
- Kidney Transplant
Programs
Cedars-Sinai clinical programs this provider is part of:
3
Research Areas
The research of Dr. Brennan focuses on how tissue injury causes inflammation and how this inflammation relates to rates of rejection of transplanted organs. Overall, the context in which transplanted organs are encountered by our immune cells is critical to determining the immune response against them. In the setting of tissue injury occurring during organ procurement, storage and transplantation, the immune system is alerted to the presence of tissue damage and initiates a response to this injury. In other words, the immune system recognizes danger signals released by the transplanted organ and can respond aggressively, attacking and damaging the organ. The goal of Dr. Brennan's research is to identify the molecules that create these signals and develop methods to prevent their release or block their recognition.
Titles
- Director, Pancreas Transplant
- Professor, Surgery
Education & Training
-
University of California, San Francisco Medical Center
Fellowship - Completed 2009
-
University of California, San Francisco Medical Center
Residency - Completed 2007
-
University of California, San Francisco Medical Center
Internship - Completed 2000
-
Harvard Medical School
Medical School - Completed 1999
-
UCLA
Degrees - Completed 1994
Achievements
-
1
Board Certifications
-
10
Awards and Honors
-
7
Publications
Board Certifications
-
Surgery-General Surgery
American Board of Surgery
Awards and Honors
- Young Investigator Award, American Transplant Congress
- Merck Index Award
- Roche Laboratories Scientist Scholarship, American Society of Transplant Surgeons
- Basic Science Faculty Development Grant, American Society of Transplantation
- Novartis Fellowship in Transplantation, American Society of Transplant Surgeons
- Clarence Gardner, M.D. Award
- Career Development Award in Liver Transplantation, American Association for the Study of Liver Diseases
- Vanguard Award, American Society of Transplant Surgeons
- Health Scholar, Duke University School of Medicine
- Career Development Award (NIAID), National Institutes of Health
Publications
A full list of this provider’s research publications can be found on their research profile or PubMed.
- Samoylova ML, Nash A, Kuchibhatla M, Barbas AS, Brennan TV. Machine perfusion of donor kidneys may reduce graft rejection. Clin Transplant. 2019 Oct;33(10):e13716. doi: 10.1111/ctr.13716. Epub 2019 Oct 15.PMID: 31541478
- Barbas AS, Lin L, McRae M, MacDonald AL, Truong T, Yang Y, Brennan TV. Heparan sulfate is a plasma biomarker of acute cellular allograft rejection. PLoS One. 2018 Aug 7;13(8):e0200877. doi: 10.1371/journal.pone.0200877. PMID: 30086133
- Pollara J, Edwards RW, Lin L, Bendersky VA, Brennan TV. Circulating mitochondria in deceased organ donors are assoicated with immune activation and early graft dysfunction. JCI Insight. 2018;3(15):e121622. https://doi.org/10.1172/jci.insight.121622.
- Brennan TV, Yang Y. PD-L1 serves as a double agent in separating GVL from GVHD. J Clin Invest. 2017 May 1;127(5):1627-1630.
- Brennan TV, Rendell VR, Yang Y. Innate immune activation by tissue injury and cell death in the setting of hematopoietic stem cell transplantation. Front Immunol. 2015 Mar 16;6:101.
- Brennan TV, Lin L, Huang X, Cardona DM, Li Z, Dredge K, Chao NJ, Yang Y. Heparan sulfate, an endogenous TLR4 agonist, promotes acute GVHD after allogeneic stem cell transplantation. Blood. 2012 Oct 4;120(14):2899-2908.
- Brennan TV, Lin L, Brandstadter JD, Rendell VR, Dredge K, Huang X, Yang Y. Heparan sulfate mimetic PG545-mediated antilymphoma effects require TLR9-dependent NK cell activation. J Clin Invest. 2016 Jan;126(1):207-219.